Latest News

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Modulim Announces CE Mark of Clarifi Imaging System for Microvascular Assessment

Modulim can now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Genius AI Detection Receives FDA Clearance

Hologic notes the new technology which the company has now made commercially available represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius 3D Mammography exam.

Levita Magnetics Announces FDA Clearance of Expanded Indication for Magnetic Surgical System for Use in Bariatric Procedures

October 22, 2018

Levita Magnetics, a company dedicated to improving the outcomes of surgical procedures through Magnetic Surgery®, today announced that the U.S. Food and Drug Administration (FDA) has granted the company an expanded indication to market the company’s first-of-its-kind Levita® Magnetic Surgical System for use in bariatric procedures. Initially indicated for use in gallbladder removal procedures, the shaftless Magnetic Surgical System reduces the number of incisions necessary for the indicated procedures.

Levita Magnetics highlights the Levita System is designed to facilitate access and visualization of the surgical site while minimizing invasiveness. In conventional laparoscopic procedures, shafted surgical instruments are introduced by fixed-position trocars inserted through incisions in the abdomen. The use of trocars is associated with risks relating to major bowel and vessel injury, incisional pain, bleeding, scarring, hernias, and infection. In addition, shafted instruments can impair surgeon visualization by cluttering the operative field, cause instrument collisions, and restrict movement as a result of their fixed pivot point. The shaftless Levita System reduces the number of incisions and trocars necessary, while also providing surgeons the ability to move instruments without the constraints of a fixed-position pivot point.

“Magnetic Surgery with the Levita System will allow us to offer a less invasive alternative to our bariatric patients. Bariatric surgery patients are interested in new options that minimize incisions and result in better cosmetic outcomes, and the Levita System has been effective in delivering these results in our preliminary experience to date,” said Dana Portenier, M.D., Chief of the Metabolic and Weight Loss Surgery division at Duke University Health System in Durham, North Carolina. “I have used the Levita System since its initial FDA clearance, and believe it is an important new option for patients electing to undergo bariatric surgery.”

According to the Centers for Disease Control and Prevention (CDC), nearly 40 percent of U.S. adults (93 million Americans) have a body mass index classifying them as obese.1 Long-term evidence from studies of bariatric surgery outcomes has demonstrated a significant benefit for weight loss as well as diabetes recovery, a lower risk of cardiovascular disease, and other metabolic and musculoskeletal benefits.2 There has been a 44 percent increase in bariatric procedures in the United States since 2011.3

“This new indication is another exciting milestone for Levita and a significant step toward fulfilling our vision to enhance patient outcomes by minimizing the footprint of surgical procedures across multiple indications and broad patient populations,” said surgeon Alberto Rodriguez-Navarro, CEO and founder, Levita Magnetics. “We are pleased that our technology allows surgeons to offer a less-invasive alternative to patients considering bariatric procedures.”

To date, patients have undergone Magnetic Surgery at leading clinical centers including the Cleveland Clinic, UT Southwestern Medical Center, Stanford University and Duke University, among others.

The Levita Magnetic Surgical System enables reduced-port laparoscopic surgical procedures designed to minimize the footprint of surgery. The system, which consists of an external magnet placed on the skin that controls a shaftless detachable grasper, enables instruments to move without the constraints of a fixed-position pivot point, and facilitates access and visualization of the surgical site.

In the United States, the Levita Magnetic Surgical System is indicated to grasp and retract the body and the fundus of the gall bladder in laparoscopic cholecystectomy procedures and the liver in bariatric procedures to facilitate access and visualization of the surgical site in patients with a BMI range of 20-60 kg/m2.


References

1 https://www.cdc.gov/nchs/data/databriefs/db288.pdf

2 Panagiotou OA, Markozannes G, Adam GP, et al. Comparative Effectiveness and Safety of Bariatric Procedures in Medicare-Eligible PatientsA Systematic Review. JAMA Surg. Published online September 05, 2018. doi:10.1001/jamasurg.2018.3326

3 https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers

Latest Posts

Fusion Antibodies and Queen’s University Belfast Awarded a £453,000 Grant from Invest Northern Ireland

The two organisations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19. Building on strong scientific knowhow, a new antibody development platform will be created that will help realise the vision of producing a breakthrough therapeutic that directly targets SARS-CoV-2.

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Kayentis, a global provider of digital data capture systems for clinical trials, today announces it has raised €7M (approx. $8.3M) in growth capital.

Kayentis is active in the global electronic Clinical Outcome Assessment (eCOA) market, which is expected to reach $2.6 billion by 2027. Market growth in eCOA – a method of capturing outcomes data electronically in clinical trials – is driven by the clinical trials industry.

Don't Miss

New England Biolabs® Introduces NEBNext® Custom RNA Depletion Design Tool and RNA Depletion Core Reagent Set for Customizable RNA Depletion

This technology has been superb for eliminating the ribosomal RNA for a range of custom projects, including tracking novel viruses in mosquitoes, longitudinal profiling for astronauts, and host-pathogen interactions in COVID samples.

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

"FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials. 

Stoke Therapeutics Announces Proposed Public Offering

November 18, 2020 Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein...